Correspondance

Je suis heureuse que 1895 ait publié mon essai intitulé « Généalogie du Carrosse d’or de Jean Renoir » (n° 62). François Albera, co-éditeur de la revue, ayant pris la liberté d’illustrer mon texte par une image extraite d’un numéro de l’Écran français (inséré p. 95), m’écrivait récemment que « ce document “complique” un peu plus la question des langues et du renoncement au français : Renoir est-il sincère (à cette date-là) ou fait-il semblant, est-ce une “mise en scène” pour sauver les appare..

Généalogie du Carrosse d’or de Jean Renoir

Pour quelles raisons le premier film mis en scène par Renoir en Europe après la Seconde Guerre mondiale – une coproduction franco-italienne – fut tourné en Italie et non en France ? Nous pensons au Carrosse d’or comme à un film de Jean Renoir, mais, un entretien réalisé avec le producteur du film, Prince Francesco Alliata, croisé avec des documents tirés des archives Renoir conservées à UCLA et à Paris, ouvrent une nouvelle perspective. Cette étude examine l’implication de Roberto Rossellini, Ingrid Bergman, Anna Magnani et Luchino Visconti ; la mise en œuvre d’une réglementation des coproductions franco-italiennes après-guerre ; les complications liées au tournage d’une production Technicolor loin du plus proche laboratoire de la firme à Londres et un plan de financement visionnaire permettant la viabilité du Carrosse d’or par la production simultanée de deux films de cape et d’épée à petit budget avec les mêmes décors et la même équipe.Why was it that the first film Jean Renoir made in Europe after WWII – a French-Italian co-production – was shot in Italy and not in France? We think of The Golden Coach as director Jean Renoir’s film, but an interview with the film’s producer, Prince Francesco Alliata, coordinated with documents from Renoir’s archives at UCLA and in Paris, and with French bank records for international co-productions, opens new vistas. The essay examines the involvement of Roberto Rossellini, Ingrid Bergman, Anna Magnani and Luchino Visconti ; the creative implementation of regulations for French-Italian co-productions in the post-WWII era ; the complications of mounting a Technicolor production far from the nearest Technicolor lab ; and the visionary financial planning that kept the production financially viable by making two sure-fire swashbucklers with the same sets and crew

Review: The Newsletter of the Literary Managers and Dramaturgs of the Americas, volume 14, issue 1

Contents include: Far From Inundated, A Word form the President, BHAGS Words of Welcome, Remarks from Conference Co-Chair Ed Sobel, Keynote Speech Given by Chuck Smith Introduced by Michele Volansky, The Telephone Monologues: Five Monologues Written for the 2003 LMDA Conference introduced by Janet Allard, Telephone, Billy, The Visitors, A Drag Queen, Choice, Don\u27t Know Much About Holly-turgy Outline, Reflections on Conference 2003, Elect Better Actors, Neo-Romantic Manifesto, Pullet Surprise-Call for Nominations, and Regional News-Know Your Regional Vice Presidents. Issue editors: D.J. Hopkins, Shelley Orr, Liz Engelman, Madeleine Oldham, Jacob Zimmerhttps://soundideas.pugetsound.edu/lmdareview/1028/thumbnail.jp

Strategies to Prevent Healthcare-Associated Infections through Hand Hygiene

Previously published guidelines provide comprehensive recommendations for hand hygiene in healthcare facilities. The intent of this document is to highlight practical recommendations in a concise format, update recommendations with the most current scientific evidence, and elucidate topics that warrant clarification or more robust research. Additionally, this document is designed to assist healthcare facilities in implementing hand hygiene adherence improvement programs, including efforts to optimize hand hygiene product use, monitor and report back hand hygiene adherence data, and promote behavior change. This expert guidance document is sponsored by the Society for Healthcare Epidemiology of America (SHEA) and is the product of a collaborative effort led by SHEA, the Infectious Diseases Society of America (IDSA), the American Hospital Association (AHA), the Association for Professionals in Infection Control and Epidemiology (APIC), and The Joint Commission, with major contributions from representatives of a number of organizations and societies with content expertise. The list of endorsing and supporting organizations is presented in the introduction to the 2014 updates

Phase 3, Randomized, 20-Month Study of the Efficacy and Safety of Bimatoprost Implant in Patients with Open-Angle Glaucoma and Ocular Hypertension (ARTEMIS 2)

Objective- To evaluate the intraocular pressure (IOP)-lowering efficacy and safety of 10 and 15 µg bimatoprost implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT). Methods- This randomized, 20-month, multicenter, masked, parallel-group, phase 3 trial enrolled 528 patients with OAG or OHT and an open iridocorneal angle inferiorly in the study eye. Study eyes were administered 10 or 15 µg bimatoprost implant on day 1, week 16, and week 32, or twice-daily topical timolol maleate 0.5%. Primary endpoints were IOP and IOP change from baseline through week 12. Safety measures included treatment-emergent adverse events (TEAEs) and corneal endothelial cell density (CECD). Results- Both 10 and 15 µg bimatoprost implant met the primary endpoint of noninferiority to timolol in IOP lowering through 12 weeks. Mean IOP reductions from baseline ranged from 6.2–7.4, 6.5–7.8, and 6.1–6.7 mmHg through week 12 in the 10 µg implant, 15 µg implant, and timolol groups, respectively. IOP lowering was similar after the second and third implant administrations. Probabilities of requiring no IOP-lowering treatment for 1 year after the third administration were 77.5% (10 µg implant) and 79.0% (15 µg implant). The most common TEAE was conjunctival hyperemia, typically temporally associated with the administration procedure. Corneal TEAEs of interest (primarily corneal endothelial cell loss, corneal edema, and corneal touch) were more frequent with the 15 than the 10 µg implant and generally were reported after repeated administrations. Loss in mean CECD from baseline to month 20 was ~ 5% in 10 µg implant-treated eyes and ~ 1% in topical timolol-treated eyes. Visual field progression (change in the mean deviation from baseline) was reduced in the 10 µg implant group compared with the timolol group. Conclusions- The results corroborated the previous phase 3 study of the bimatoprost implant. The bimatoprost implant met the primary endpoint and effectively lowered IOP. The majority of patients required no additional treatment for 12 months after the third administration. The benefit-risk assessment favored the 10 over the 15 µg implant. Studies evaluating other administration regimens with reduced risk of corneal events are ongoing. The bimatoprost implant has the potential to improve adherence and reduce treatment burden in glaucoma

Convalescent plasma in patients admitted to hospital with COVID-19 (RECOVERY): a randomised controlled, open-label, platform trial

SummaryBackground Azithromycin has been proposed as a treatment for COVID-19 on the basis of its immunomodulatoryactions. We aimed to evaluate the safety and efficacy of azithromycin in patients admitted to hospital with COVID-19.Methods In this randomised, controlled, open-label, adaptive platform trial (Randomised Evaluation of COVID-19Therapy [RECOVERY]), several possible treatments were compared with usual care in patients admitted to hospitalwith COVID-19 in the UK. The trial is underway at 176 hospitals in the UK. Eligible and consenting patients wererandomly allocated to either usual standard of care alone or usual standard of care plus azithromycin 500 mg once perday by mouth or intravenously for 10 days or until discharge (or allocation to one of the other RECOVERY treatmentgroups). Patients were assigned via web-based simple (unstratified) randomisation with allocation concealment andwere twice as likely to be randomly assigned to usual care than to any of the active treatment groups. Participants andlocal study staff were not masked to the allocated treatment, but all others involved in the trial were masked to theoutcome data during the trial. The primary outcome was 28-day all-cause mortality, assessed in the intention-to-treatpopulation. The trial is registered with ISRCTN, 50189673, and ClinicalTrials.gov, NCT04381936.Findings Between April 7 and Nov 27, 2020, of 16 442 patients enrolled in the RECOVERY trial, 9433 (57%) wereeligible and 7763 were included in the assessment of azithromycin. The mean age of these study participants was65·3 years (SD 15·7) and approximately a third were women (2944 [38%] of 7763). 2582 patients were randomlyallocated to receive azithromycin and 5181 patients were randomly allocated to usual care alone. Overall,561 (22%) patients allocated to azithromycin and 1162 (22%) patients allocated to usual care died within 28 days(rate ratio 0·97, 95% CI 0·87–1·07; p=0·50). No significant difference was seen in duration of hospital stay (median10 days [IQR 5 to >28] vs 11 days [5 to >28]) or the proportion of patients discharged from hospital alive within 28 days(rate ratio 1·04, 95% CI 0·98–1·10; p=0·19). Among those not on invasive mechanical ventilation at baseline, nosignificant difference was seen in the proportion meeting the composite endpoint of invasive mechanical ventilationor death (risk ratio 0·95, 95% CI 0·87–1·03; p=0·24).Interpretation In patients admitted to hospital with COVID-19, azithromycin did not improve survival or otherprespecified clinical outcomes. Azithromycin use in patients admitted to hospital with COVID-19 should be restrictedto patients in whom there is a clear antimicrobial indication

Retrospective evaluation of whole exome and genome mutation calls in 746 cancer samples

Funder: NCI U24CA211006Abstract: The Cancer Genome Atlas (TCGA) and International Cancer Genome Consortium (ICGC) curated consensus somatic mutation calls using whole exome sequencing (WES) and whole genome sequencing (WGS), respectively. Here, as part of the ICGC/TCGA Pan-Cancer Analysis of Whole Genomes (PCAWG) Consortium, which aggregated whole genome sequencing data from 2,658 cancers across 38 tumour types, we compare WES and WGS side-by-side from 746 TCGA samples, finding that ~80% of mutations overlap in covered exonic regions. We estimate that low variant allele fraction (VAF < 15%) and clonal heterogeneity contribute up to 68% of private WGS mutations and 71% of private WES mutations. We observe that ~30% of private WGS mutations trace to mutations identified by a single variant caller in WES consensus efforts. WGS captures both ~50% more variation in exonic regions and un-observed mutations in loci with variable GC-content. Together, our analysis highlights technological divergences between two reproducible somatic variant detection efforts